Filing Overview
This Form 8-K was filed by MedTech Acquisition Corporation, not Trisalus Life Sciences, Inc. It reports an event occurring on March 18, 2021, and was signed on March 22, 2021. The filing concerns the appointment of a director and does not present operating or financial results.
Business Context and Reporting Period
MedTech Acquisition Corporation is a Delaware corporation with securities listed on Nasdaq under the symbols MTACU, MTAC, and MTACW. The company appointed Thierry Thaure to its board of directors on March 18, 2021.
Financial Metrics and Capitalization
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Material Changes and Governance
- Thierry Thaure was appointed as a director effective March 18, 2021.
- Mr. Thaure has more than 35 years of medical-device industry experience, including executive and board roles at Triflo Cardiovascular, Cephea Valve Technologies, EndoGastric Solutions, Accuray, Intuitive Surgical, and other medical technology companies.
- The board determined that his medical technology, public-company, and board experience qualified him for service.
- The company stated that there were no related-party transactions with Mr. Thaure requiring disclosure under Item 404(a) of Regulation S-K.
- Mr. Thaure entered into a letter agreement and indemnification agreement substantially similar to those entered into by the other directors in connection with the company’s initial public offering.
Outlook, Risks, and Unusual Items
The filing provides no financial guidance or management outlook. No material contingencies or unusual financial items are disclosed. The principal reported change is the addition of a director with extensive medical-device industry experience.
Investor Verification Items
- Verify the issuer identity: the supplied filing is for MedTech Acquisition Corporation rather than Trisalus Life Sciences, Inc.
- Review the director appointment, letter agreement, and indemnification agreement for their specific terms.
- Confirm whether subsequent filings describe additional governance changes, business-combination activity, or financial developments.
- Check the company’s Nasdaq-listed securities and trading symbols against current records.